MNOV · Medicinova Inc
What's happening
- MNOV is up 2.92% today, trading at $1.41. — Live quote
- Volume today (363) is well below its 3-month average of 253,919. (Finnhub fundamentals)
- Reports earnings on 2026-11-11, 20 days away. (Finnhub earnings calendar)
- Last quarter's EPS beat estimates: $-0.05 actual vs. $-0.06 estimated (+22.6%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Aggregate ratings for 2026-10-01 (10 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
Earnings Trends (Quarterly EPS Actual vs Estimate)
Valuation Measures & Ratios
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $61.1M | $70.9M | $63.3M | $62.3M | $69.9M |
| P/E | -5.44 | -6.01 | -5.25 | -5.36 | -6.30 |
| Price/Sales | 67.63 | — | — | — | — |
| Price/Book | 1.64 | 1.80 | 1.44 | 1.33 | 1.40 |
| EV/Revenue | 39.49 | — | — | — | — |
| EV/EBITDA | -2.89 | -3.35 | -2.28 | — | — |
| ROE | -30.14% | -29.90% | -27.40% | -24.81% | -22.23% |
| ROA | -27.78% | -27.59% | -25.32% | -23.33% | -21.17% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Revenue growth is 240.6% on the provider's reported measure. Finnhub fundamentals ↗
- Trailing 52-week price return is +12.4%. Finnhub market metrics ↗
Potential concerns
- Net profit margin is -1168.2%. Finnhub fundamentals ↗
- Latest SEC filing is Form 4, filed 2026-09-29; review it for current changes and risks. SEC EDGAR ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on MNOV
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $458.4K | $187.0K | $123.3K | $134.6K | — | — | — | — |
| Operating income | -$2.5M | -$2.8M | -$3.4M | -$3.6M | -$3.2M | -$3.3M | -$3.0M | -$3.1M |
| Net income | -$2.3M | -$2.6M | -$3.1M | -$3.3M | -$2.9M | -$2.9M | -$2.6M | -$2.8M |
| EPS (diluted) | $-0.05 | $-0.05 | $-0.06 | $-0.07 | $-0.06 | $-0.06 | $-0.05 | $-0.06 |
| EPS (basic) | $-0.05 | $-0.05 | $-0.06 | $-0.07 | $-0.06 | $-0.06 | $-0.05 | $-0.06 |
| Operating margin | -$554 | -$1.5K | -$2.7K | -$2.7K | — | — | — | — |
| Net margin | -$505 | -$1.4K | -$2.5K | -$2.4K | — | — | — | — |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Aug '25 | Jun '25 | Mar '25 | Dec '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $40.4M | $42.7M | $45.6M | $47.6M | — | $49.8M | $52.4M | $55.9M |
| Total liabilities | $3.2M | $3.3M | $4.0M | $3.6M | — | $3.0M | $2.5M | $3.4M |
| Stockholders' equity | $37.3M | $39.4M | $41.6M | $44.0M | — | $46.9M | $49.9M | $52.5M |
| Total current assets | $25.9M | $28.1M | $31.0M | $32.9M | — | $35.1M | $37.7M | $41.1M |
| Total current liabilities | $3.0M | $3.1M | $3.8M | $3.3M | — | $2.6M | $2.1M | $3.0M |
| Cash & equivalents | $25.4M | $27.3M | $30.8M | $32.6M | — | $34.3M | $36.6M | $40.4M |
| Marketable securities (current) | — | — | — | — | — | — | — | — |
| Accounts receivable | $0 | $245.1K | $0 | $0 | — | $134.6K | — | $0 |
| Marketable securities (non-current) | — | — | — | — | — | — | — | — |
| Property, plant & equipment | $9.8K | $14.9K | $8.3K | $12.9K | — | $15.4K | $20.4K | $25.5K |
| Goodwill | $9.6M | $9.6M | $9.6M | $9.6M | — | $9.6M | $9.6M | $9.6M |
| Other non-current assets | $0 | $0 | $19.0K | $19.0K | — | $19.0K | $19.0K | $19.0K |
| Accounts payable | $950.5K | $852.4K | $625.0K | $746.0K | — | $569.4K | $718.9K | $1.1M |
| Accrued liabilities | — | — | — | — | — | — | — | — |
| Deferred revenue (current) | $0 | $428.3K | $370.2K | $521.9K | $500.0K | — | — | — |
| Short-term debt | — | — | — | — | — | — | — | — |
| Long-term debt | — | — | — | — | — | — | — | — |
| Other non-current liabilities | $0 | $0 | $17.1K | $74.4K | — | $117.0K | $165.2K | $211.5K |
| Common stock & paid-in capital | $49.2K | $49.2K | $49.2K | $49.0K | — | $49.0K | $49.0K | $49.0K |
| Retained earnings | -$443.6M | -$441.3M | -$438.7M | -$435.9M | — | -$432.9M | -$429.6M | -$426.8M |
| Accumulated other comprehensive income (loss) | -$127.4K | -$128.1K | -$127.2K | -$126.8K | — | -$127.4K | -$130.1K | -$135.2K |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$1.9M | -$3.5M | -$2.0M | -$1.7M | -$2.3M | -$3.8M | -$1.9M | -$2.0M |
| Investing cash flow | $0 | -$10.8K | $0 | -$2.9K | $0 | $0 | $1 | $193 |
| Financing cash flow | — | — | $244.0K | — | — | — | $0 | — |
| Free cash flow | -$1.9M | -$3.5M | -$2.0M | -$1.7M | -$2.3M | -$3.8M | -$1.9M | -$2.0M |
| Capital expenditures | $0 | $10.8K | $0 | $2.9K | $0 | $0 | -$2 | $6 |
| Depreciation & amortization | $5.0K | $4.3K | $4.6K | $5.3K | $5.1K | $5.2K | $5.2K | $5.2K |
| Share-based compensation | $176.8K | $407.8K | $180.6K | $157.7K | $204.9K | $285.9K | $264.0K | $504.9K |
| Deferred income taxes | — | — | — | — | — | — | — | — |
| Change in accounts receivable | -$245.1K | $245.1K | — | — | $134.6K | $0 | — | — |
| Purchases of investments | — | — | — | — | — | — | — | — |
| Share repurchases | — | — | — | — | — | — | — | — |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Revenue | $409.7K | — | $1.0M | — | $4.0M |
| Operating income | -$13.3M | -$12.7M | -$9.9M | -$14.6M | -$10.2M |
| Net income | -$12.0M | -$11.0M | -$8.6M | -$14.1M | -$10.1M |
| EPS (diluted) | $-0.24 | $-0.23 | $-0.17 | $-0.29 | $-0.21 |
| EPS (basic) | $-0.24 | $-0.23 | $-0.17 | $-0.29 | $-0.21 |
| Operating margin | -$3.2K | — | -$990 | — | -$253 |
| Net margin | -$2.9K | — | -$857 | — | -$251 |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $45.6M | $55.9M | $66.3M | $74.2M | $87.4M |
| Total liabilities | $4.0M | $3.4M | $3.9M | $3.9M | $3.7M |
| Stockholders' equity | $41.6M | $52.5M | $62.4M | $70.2M | $83.7M |
| Total current assets | $31.0M | $41.1M | $51.2M | $59.0M | $72.0M |
| Total current liabilities | $3.8M | $3.0M | $3.3M | $3.2M | $2.8M |
| Cash & equivalents | $30.8M | $40.4M | $51.0M | $18.5M | $71.4M |
| Marketable securities (current) | — | — | — | $40.0M | — |
| Property, plant & equipment | $8.3K | $25.5K | $45.8K | $45.3K | $57.6K |
| Goodwill | $9.6M | $9.6M | $9.6M | $9.6M | $9.6M |
| Other non-current assets | $19.0K | $19.0K | $74.2K | $92.8K | $115.5K |
| Accounts payable | $625.0K | $1.1M | $1.0M | $424.6K | $402.7K |
| Accrued liabilities | — | — | — | — | — |
| Deferred revenue (current) | $370.2K | — | — | — | — |
| Short-term debt | — | — | — | — | — |
| Long-term debt | — | — | — | — | — |
| Other non-current liabilities | $17.1K | $211.5K | $410.7K | $523.6K | $694.7K |
| Common stock & paid-in capital | $49.2K | $49.0K | $49.0K | $49.0K | $49.0K |
| Retained earnings | -$438.7M | -$426.8M | -$415.7M | -$407.1M | -$393.1M |
| Accumulated other comprehensive income (loss) | -$127.2K | -$135.2K | -$118.1K | -$115.3K | -$98.9K |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$9.8M | -$10.6M | -$7.4M | -$12.9M | -$9.4M |
| Investing cash flow | -$2.9K | -$697 | $39.9M | -$40.0M | -$28.7K |
| Financing cash flow | $244.0K | $0 | — | $7.9K | $20.8M |
| Free cash flow | -$9.8M | -$10.6M | -$7.5M | -$12.9M | -$9.4M |
| Capital expenditures | $2.9K | $895 | $21.3K | $5.0K | $28.7K |
| Depreciation & amortization | $20.1K | $21.1K | $20.3K | $17.7K | $26.1K |
| Share-based compensation | $829.1K | $1.2M | $710.7K | $642.5K | $1.7M |
| Deferred income taxes | — | — | — | — | — |
| Share repurchases | — | — | — | — | — |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding MNOV as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2026-09-25 to 2026-09-25
Recent transactions
- Insiders have net sold 640,000 shares over the last 182 days, across 0 purchases and 1 sale.
- Most recent: 3D Investment Partners Pte. Ltd. (Formerly 10% Owner) — Open market sale of 640,000 shares on 2026-09-25.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| 3D Investment Partners Pte. Ltd. | Formerly 10% Owner | Open market sale | 2026-09-25 | 640,000 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-25 | 3D Investment Partners Pte. Ltd. | Formerly 10% Owner | Open market sale | 640,000 | $2.70 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-21 23:17 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-09-29 | 4 | 2026-09-25 | View on SEC.gov → |
| 2026-09-28 | 8-K | 2026-09-23 | View on SEC.gov → |
| 2026-09-02 | 8-K | 2026-08-31 | View on SEC.gov → |
| 2026-08-19 | 8-K | 2026-08-17 | View on SEC.gov → |
| 2026-08-13 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-06-25 | 4 | 2026-06-23 | View on SEC.gov → |
| 2026-06-25 | 4 | 2026-06-23 | View on SEC.gov → |
| 2026-06-25 | 4 | 2026-06-23 | View on SEC.gov → |
| 2026-06-24 | 8-K | 2026-06-23 | View on SEC.gov → |
| 2026-05-14 | 10-Q | 2026-03-31 | View on SEC.gov → |
| 2026-03-10 | 10-K | 2025-12-31 | View on SEC.gov → |
| 2026-02-20 | 8-K | 2026-02-20 | View on SEC.gov → |
Recent news
Headlines about MNOV (Medicinova Inc). Links open the publisher — we don’t host full articles.
-
MNOV Oct 2026 5.000 call (MNOV261016C00005000) interactive stock chart
Yahoo Finance UK · 2026-10-17 -
MediciNova reports mixed MN-001 results. Analysts give MediciNova stock a Moderate Buy rating - ad-hoc-news.de
ad-hoc-news.de · 2026-10-15 -
MediciNova CEO Provides Shareholder Update
Yahoo · 2026-10-12 -
MediciNova Provides Update On Recent Topline Results Of Its Phase 2 Clinical Trial Evaluating MN-001 For Treatment Of Nonalcoholic Fatty Liver Disease And Hypertriglyceridemia Associated With Type 2 Diabetes Mellitus; At
Benzinga · 2026-10-12 -
MediciNova to Participate in the Maxim Growth Summit
Yahoo Finance · 2026-10-06 -
MediciNova Drug Falls Short on Liver Fat Parameter, Stock Tumbles
Yahoo Finance · 2026-09-28 -
MediciNova Shares Fall After Phase 2 Tipelukast Trial Misses Primary Endpoints
Yahoo Finance · 2026-09-28 -
MediciNova stock tumbles on mixed Phase 2 NAFLD trial data
Yahoo Finance · 2026-09-28
No headlines in this category right now — try “All”.